Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples

Clinical Biochemistry

Volumn 43, Issue 10-11, 2010, Pages 891-898

  Zaczek, Anna ^a   Markiewicz, Aleksandra ^a   Jaśkiewicz, Janusz ^a   Pieńkowski, Tadeusz ^b   Rhone, Piotr ^c   Jassem, Jacek ^a   Wełnicka Jaśkiewicz, Marzena ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c Cancer Center   (Poland)

Author keywords

Breast cancer; Gene copy number; Hydrolysis probe; Real time PCR; Topoisomerase II alpha

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; TOPOISOMERASE II ALPHA; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; OLIGONUCLEOTIDE PROBE; TUMOR ANTIGEN;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; ENZYME ASSAY; GENE AMPLIFICATION; GENE PROBE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROGNOSIS; PROTEIN HYDROLYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; ADULT; AGED; BREAST TUMOR; EVALUATION STUDY; FEMALE; GENE DOSAGE; GENETICS; HYDROLYSIS; MIDDLE AGED; OLIGONUCLEOTIDE PROBE; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE DOSAGE; HUMANS; HYDROLYSIS; MIDDLE AGED; OLIGONUCLEOTIDE PROBES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; DNA TOPOISOMERASES, TYPE II;

EID: 77953725585     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.04.060     Document Type: Article

References (44)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Austin C.A., Marsh K.L. Eukaryotic DNA topoisomerase II β. BioEssays 1998, 20:215-226.
3. Taagepera S., Rao P.N., Drake F.H., Gorbsky G.J. DNA topoisomerase IIa is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2. Proc Natl Acad Sci USA 1993, 90:8407-8411.
4. Rattner J.B., Hendzel M.J., Furbee C.S., Muller M.T., Bazett-Jones D.P. Topoisomerase II α is associated with the mammalian centromere in a cell cycle- and species-specific manner and is required for proper centromere/kinetochore structure. J Cell Biol 1996, 134:1097-1107.
5. Holm C., Stearns T., Botstein D. DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage. Mol Cell Biol 1989, 9:159-168.
6. Burden D.A., Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. BBA 1998, 1400:139-154.
7. Heck M.M.S., Hittelmann W.N., Earnshaw W.C. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle 1988, 85:1086-1090.
8. Fortune J.M., Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Progress in Nucleic Acid Research and Molecular Biology 2000, 221-254. Academic Press, San Diego. K. Moldave (Ed.).
9. Nitiss J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009, 9:338-350.
10. Żaczek A., Wełnicka-Jaśkiewicz M., Bielawski K.P., Jaśkiewicz J., Badzio A., Olszewsk W., et al. Gene copy numbers of HER family in breast cancer. J Cancer Res Clin Oncol 2008, 134:271-279.
11. Ross J.S., Harbeck N. Prognostic and predictive factors overview. Molecular Oncology of Breast Cancer 2005, 128-141. Jones & Bartlett Publishers, Sudbury. J.S. Ross, G.N. Hortobagyi (Eds.).
12. Slamon D., Clark G., Wong S., Levin W., Ullrich A., McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
13. Järvinen T.A.H., Tanner M., Rantanen V., Bärlund M., Borg Å., Grènman S., et al. Amplification and deletion of topoisomerase IIa associate with ErbB-2 amplification and affect sensitivity to topoisomerase II Inhibitor doxorubicin in breast cancer. Am J Pathol 2000, 156:839-847.
14. Lehmann U., Glöckner S., Kleeberger W., Feist H., Wasielewski R.v., Kreipe H. Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol 2000, 156:1855-1864.
15. Park K., Kim J., Lim S., Han S. Topoisomerase II-a (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eu J Cancer 2003, 39:631-634.
16. Knoop A.S., Knudsen H., Balslev E., Rasmussen B.B., Overgaard J., Nielsen K.V., et al. Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005, 23:7483-7490.
17. Arriola E., Rodriguez-Pinilla S.M., Lambros M.B.K., Jones R.L., James K., Savage K., Smith I.E., Dowsett M., Reis-Filho J.S. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 2007, 106:181-189.
18. Colozza M., Azambuja E., Cardoso F., Sotiriou C., Larsimont D., Piccart M.J. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol 2005, 16:1723-1739.
19. Durbecq V., Paesmans M., Cardoso F., Desmedt C., Leo A.D., Chan S., Friedrichs K., Pinter T., Belle S.V., Murray E., Bodrogi I., Walpole E., Lesperance B., Korec S., Crown J., Simmonds P., Perren T.J., Leroy J.-Y., Rouas G., Sotiriou C., Piccart M., Piccart M., Larsimont D. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 2004, 3:1207-1214.
20. Nielsen K.V., Ejlertsen B., Møller S., Jørgensen J.T., Knoop A., Knudsen H., et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol 2008, 47:725-734.
21. Rudolph P., Olsson H., Bonatz G., Ratjen V., Bolte H., Baldetorp B., et al. Correlation between p53, c-erbB-2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 1999, 187:207-216.
22. Rudolph P., MacGrogan G., Bonichon F., Frahm S.O., Mascarel I.D., Trojani M., Durand M., Avril A., Coindre J.M., Parwaresch R. Prognostic significance of Ki67 and topoisomerase IIα expression in infiltrating ductal carcinoma of the breast. Breast Cancer Res Treat 1999, 55:61-71.
23. Depowski P.L., Rosenthal S.I., Brien T.P., Stylos S., Johnson R.L., Ross J.S. Topoisomerase IIa expression in breast cancer: correlation with outcome variables. Mod Pathol 2000, 13:542-547.
24. Ross J.S., Fletcher J.A., Linette G.P., Stec J., Clark E., Ayers M., et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003, 8:307-325.
25. Cardoso F., Durbecq V., Larsimont D., Paesmans M., Leroy J., Rouas G., et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-α gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 2004, 24:201-209.
26. Mundle S.D., Koska R.J. Fluorescence in situ hybridization: a major milestone in luminous cytogenetics. Molecular diagnostics: for the clinical laboratorian 2006, 189-202. Humana Press, New Jersey. W.B. Coleman, G.J. Tsongalis (Eds.).
27. Hanna W.M., Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Modern Pathol 2006, 19:481-487.
28. Bièche I., Olivi M., Champème M.-H., Vidaud D., Lidereau R., Vidaud M. Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer 1998, 78:661-666.
29. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:2002-2007.
30. Murthy S.K., Magliocco A.M., Demetrick D.J. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIa genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization. Arch Pathol Lab Med 2005, 129:39-46.
31. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
32. Gjerdrum L.M., Sorensen B.S., Kjeldsen E., Sorensen F.B., Nexo E., Hamilton-Dutoit S. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma. J Mol Diagn 2004, 6:42-51.
33. Wigler M., Hicks J., Norton L., Zettenberg A. Use of roma for characterizing genomic rearrangements. T.U.P.a.T. Office, ed., Vol 2007, United States.
34. McArthur H., Tan L., Patil S., Wigler M., Hudis C., Hicks J., et al. High resolution representational oligonucleotide microarray analysis (ROMA) suggests that TOPO2 and HER2 co-amplification is uncommon in human breast cancer. Cancer Res 2009, 69.
35. Bhargava R., Lal P., Chen B. HER-2/neu and topoisomerase IIα gene amplification and protein expression in invasive breast carcinomas. Anat Pathol 2005, 123:889-895.
36. Park K., Han S., Gwak G.-H., Kim H.-J., Kim J., Kim K.-M. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer. Breast Cancer Res Treat 2006, 98:337-342.
37. Lehmann U., Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001, 25:409-418.
38. O'Malley F.P., Chia S., Tu D., Shepherd L.E., Levine M.N., Bramwell V.H., et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009, 101:644-650.
39. Bouchalová K., Trojanec R., Kolár Z., Cwiertka K., Cernáková I., Mihál V., et al. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. Neoplasma 2006, 53:393-401.
40. Usha L., Tabesh B., Morrison L.E., Rao R.D., Jacobson K., Zhu A., et al. Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts. J Hematol Oncol 2008, 1:12. 10.1186/1756-8722-1-12.
41. Arriola E., Marchio C., Tan D.S., Drury S.C., Lambros M.B., Natrajan R., et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008, 88:491-503.
42. Järvinen T.A.H., Kononen J., Pelto-Huikko M., Isola J. Expression of topoisomerase IIa is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 1996, 148:2073-2082.
43. Tanner M., Isola J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P., Malmström P., et al. Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006, 24:2428-2436.
44. Bofin A.M., Ytterhus B., Hagmar B.M. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 2003, 14:314-319.